Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516127 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3516126 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3520235 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3516124 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL5085656 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3516343 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3520438 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3520440 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3516344 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 | |
| SCHEMBL3516341 | 0.84 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2CYP2D6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-8877975-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.